Pain Therapeutics and King Pharmaceuticals entered into research & development agreement to co-develop and commercialize Pain Therapeutics’ improved opioid painkillers such as Remoxy™ and Oxytrex™. The deal could be worth up to US$400 M to Pain Therapeutics if specific milestones and sales targets are met.